JP5889273B2 - 染色組成物 - Google Patents
染色組成物 Download PDFInfo
- Publication number
- JP5889273B2 JP5889273B2 JP2013502515A JP2013502515A JP5889273B2 JP 5889273 B2 JP5889273 B2 JP 5889273B2 JP 2013502515 A JP2013502515 A JP 2013502515A JP 2013502515 A JP2013502515 A JP 2013502515A JP 5889273 B2 JP5889273 B2 JP 5889273B2
- Authority
- JP
- Japan
- Prior art keywords
- dye
- tissue
- staining
- dyeing composition
- blue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 144
- 238000004043 dyeing Methods 0.000 title claims description 52
- 238000010186 staining Methods 0.000 claims description 98
- 239000000975 dye Substances 0.000 claims description 85
- 238000001356 surgical procedure Methods 0.000 claims description 42
- 239000002202 Polyethylene glycol Substances 0.000 claims description 35
- 229920001223 polyethylene glycol Polymers 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 34
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 claims description 30
- 230000001965 increasing effect Effects 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 27
- 239000007788 liquid Substances 0.000 claims description 23
- 229920003169 water-soluble polymer Polymers 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- BPHHNXJPFPEJOF-GPTZEZBUSA-J [Na+].[Na+].[Na+].[Na+].COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S([O-])(=O)=O)S([O-])(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S([O-])(=O)=O)S([O-])(=O)=O)c(OC)c1 Chemical compound [Na+].[Na+].[Na+].[Na+].COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S([O-])(=O)=O)S([O-])(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S([O-])(=O)=O)S([O-])(=O)=O)c(OC)c1 BPHHNXJPFPEJOF-GPTZEZBUSA-J 0.000 claims description 4
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims description 4
- 229960004657 indocyanine green Drugs 0.000 claims description 4
- -1 methoxy, amino, hydroxyl Chemical group 0.000 claims description 4
- RBDJQFKUZPMOFH-UHFFFAOYSA-I pentasodium;3-amino-4-[[4-[4-[(2-amino-3,6-disulfonatonaphthalen-1-yl)diazenyl]-3-sulfonatophenyl]phenyl]diazenyl]naphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(N)=C1N=NC1=CC=C(C=2C=C(C(N=NC=3C4=CC=C(C=C4C=C(C=3N)S([O-])(=O)=O)S([O-])(=O)=O)=CC=2)S([O-])(=O)=O)C=C1 RBDJQFKUZPMOFH-UHFFFAOYSA-I 0.000 claims description 4
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 3
- DGOBMKYRQHEFGQ-UHFFFAOYSA-L acid green 5 Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 DGOBMKYRQHEFGQ-UHFFFAOYSA-L 0.000 claims description 3
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 claims description 3
- 125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 claims description 3
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 3
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 claims description 3
- 229930187593 rose bengal Natural products 0.000 claims description 3
- 229940081623 rose bengal Drugs 0.000 claims description 3
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 claims description 3
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 claims description 3
- RTMBGDBBDQKNNZ-UHFFFAOYSA-L C.I. Acid Blue 3 Chemical compound [Ca+2].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=C(O)C=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1.C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=C(O)C=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 RTMBGDBBDQKNNZ-UHFFFAOYSA-L 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 238000001246 colloidal dispersion Methods 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 235000012736 patent blue V Nutrition 0.000 claims description 2
- 239000004177 patent blue V Substances 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 239000008154 viscoelastic solution Substances 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 113
- 210000001525 retina Anatomy 0.000 description 63
- 210000001508 eye Anatomy 0.000 description 56
- 210000000695 crystalline len Anatomy 0.000 description 48
- 239000002775 capsule Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 24
- 208000002367 Retinal Perforations Diseases 0.000 description 22
- 208000001351 Epiretinal Membrane Diseases 0.000 description 21
- 208000029233 macular holes Diseases 0.000 description 19
- 208000031471 Macular fibrosis Diseases 0.000 description 17
- 210000004379 membrane Anatomy 0.000 description 17
- 239000012528 membrane Substances 0.000 description 17
- 230000002207 retinal effect Effects 0.000 description 16
- 206010038848 Retinal detachment Diseases 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 12
- 230000004264 retinal detachment Effects 0.000 description 12
- 239000004372 Polyvinyl alcohol Substances 0.000 description 11
- 229920002451 polyvinyl alcohol Polymers 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 208000002177 Cataract Diseases 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 231100000241 scar Toxicity 0.000 description 9
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 8
- 206010038934 Retinopathy proliferative Diseases 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 8
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 239000003855 balanced salt solution Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 description 4
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000001886 ciliary effect Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 210000003786 sclera Anatomy 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010025421 Macule Diseases 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000000412 dendrimer Substances 0.000 description 3
- 229920000736 dendritic polymer Polymers 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 2
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 206010012692 Diabetic uveitis Diseases 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 229940082649 blood substitutes and perfusion irrigating solutions Drugs 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
- BPHHNXJPFPEJOF-UHFFFAOYSA-J chembl296966 Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC(S([O-])(=O)=O)=C(N)C2=C(O)C(N=NC3=CC=C(C=C3OC)C=3C=C(C(=CC=3)N=NC=3C(=C4C(N)=C(C=C(C4=CC=3)S([O-])(=O)=O)S([O-])(=O)=O)O)OC)=CC=C21 BPHHNXJPFPEJOF-UHFFFAOYSA-J 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 108010014606 glutathione-bicarbonate-Ringer solution Proteins 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 2
- 229960004359 iodixanol Drugs 0.000 description 2
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 2
- 239000013010 irrigating solution Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical group [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920000962 poly(amidoamine) Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- YIVJSMIYMAOVSJ-UHFFFAOYSA-M sodium;hydron;phosphonato phosphate Chemical compound [Na+].OP(O)(=O)OP(O)([O-])=O YIVJSMIYMAOVSJ-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GOPUCFKUFOFEIC-UHFFFAOYSA-N 2-methyl-1,3-oxazolidine Chemical compound CC1NCCO1 GOPUCFKUFOFEIC-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical class FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Chemical class 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 208000009857 Microaneurysm Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Chemical class 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000009799 cystectomy Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000001542 lens epithelial cell Anatomy 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- FHBNPEJLQIGOPC-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)acetamide Chemical compound CC(=O)NCC(O)CO FHBNPEJLQIGOPC-UHFFFAOYSA-N 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 150000002896 organic halogen compounds Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 108091033319 polynucleotide Chemical class 0.000 description 1
- 239000002157 polynucleotide Chemical class 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 239000003190 viscoelastic substance Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0023—Di-or triarylmethane dye
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0028—Oxazine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/003—Thiazine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0071—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form solution, solute
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Optics & Photonics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
-本発明の染色組成物を、眼組織または眼組織の一部の表面に適用する工程、および
-染色組成物を、眼組織または眼組織の一部の上に沈降またはその中に浸透させる工程
を含む、眼組織またはその一部を染色するための方法をさらに対象としている。
17%PEG 600溶液、0.9%NaCl溶液および4%PEG3350の密度を、比重びんを用いて測定した。したがって、298KにおいてPEG600溶液の密度を測定すると1013kg・m-3であり、NaCl溶液の密度は、1003kg・m-3であり、PEG3350溶液の密度は、1004 kg・m-3であった。これらの結果は溶液中にPEGが存在することにより、その密度が増大することを明示している。
3350g/mol(PEG 3350)の分子量を有する、0.15重量%のトリパンブルー(TB)および10重量%ポリエチレングリコールを含んだ100μLの染色組成物を、4mLのリン酸緩衝生理食塩水で満たしたガラスビーカー中にピペットで約13秒かけて放出した。
さらに、染色組成物がガラスビーカーの含有物と混和しないことを、目視検査によって観察した。図2(g)を見れば分かるように、染料ホルダーが空になった後でさえ、染色組成物は、染料を適用した領域上、すなわち、ガラスビーカーの底部上に局在化したままであることをさらに観察した。
本発明の染色組成物は、対象組織に対して、「空気中で」、すなわち、ガラス質の空洞部を空気で完全に満たして投与されるか、または、「平衡塩類溶液中」、すなわち、硝子体空洞部を平衡塩類溶液で完全に満たして投与される。染料は、染料を適用している領域上に局在化したままになる。すべての過剰な染料の除去後には、対象組織が染色されて、内境界膜または網膜上膜の選択的除去が可能になる。
2つの染色組成物中の生体染料トリパンブルーの分解を、長時間測定した。第1の染色組成物は、0.25重量%のトリパンブルーおよびリン酸緩衝塩溶液(0.25重量%の一リン酸二ナトリウム12H2O、0.036重量%の二リン酸一ナトリウム2H2Oおよび0.8重量%の塩化ナトリウム)を含んでいた。第2の染色組成物は、0.25重量%のトリパンブルー、17重量%のポリエチレングリコール600(PEG600)およびリン酸緩衝塩溶液(0.25重量%の一リン酸二ナトリウム12H2O(0.25重量%)、二リン酸一ナトリウム2H2O(0.036重量%))を含んでいた。
親水性ポリマーを含む溶液中のトリパンブルーの安定性は、ポリマーの性質に依存していると思われる。図3は、4%(w/v)のポリエチレングリコール(PEG、Mw約3350)の存在下、4%(w/v)のポリビニルアルコール(PVA、Mw約13,000〜23,000)の存在下、および4%(w/v)のポリビニルピロリドン(PVP、Mw約10,000)の存在下のそれぞれで、7日間の間70℃にさらす前およびさらした後における、(最終濃度0.15% w/vの)トリパンブルー溶液の正規化した吸光度を示している。相対的な差スペクトルは、図4において比較(図3のトリパンブルーのスペクトルを差し引いて算出)されており、トリパンブルーの方が、PEG溶液中ではより安定であることがはっきり示されている。さらに、PVPの存在下では、元々の吸光度のうちの相当な量が消失していることが見いだされた。
Claims (11)
- 生体染料と、水溶性ポリマーである密度および粘度増大化合物とを含み、
前記染料が、ブリリアントブルーG、ブリリアントブルーR、パテントブルーV、シカゴスカイブルー6B、トリパンブルー、トリパンレッド、ブリリアントクレシルブルー、インドシアニングリーンおよび下記式を有する化合物
前記水溶性ポリマーがポリエチレングリコールである、
眼組織または眼組織の一部を染色する処置において使用するための染色組成物であって、前記処置が、眼科手術の一部である、染色組成物。 - 密度増大化合物が、50〜500,000g/molの分子量を有する、請求項1に記載の染色組成物。
- 前記染料が、第1および第2の染料を含み、第1の染料が、トリパンブルーまたはシカゴスカイブルー6Bであり、第2の染料が、ブリリアントブルーG、ライトグリーンSF黄口、フェノールレッド、クロロフェノールレッド-β-D-ガラクトピラノシド、ローズベンガル、フロキシンBおよびサフラニンTからなる群より選択される、請求項1または2に記載の染色組成物。
- 前記第1の染料が、トリパンブルーであり、前記第2の染料が、ブリリアントブルーGである、請求項3に記載の染色組成物。
- 染色組成物の染料中の第1の染料と第2の染料の重量比が、1:1から100:1の間である、請求項3または4に記載の染色組成物。
- 塩化ナトリウム、塩化カリウム、塩化カルシウム、塩化マグネシウム、またはそれらの組合せからなる群より選択される塩をさらに含む、請求項1から5のいずれかに記載の染色組成物。
- 水溶液、コロイド分散液または粘性もしくは粘弾性の溶液であり、染色組成物中の密度増大化合物の濃度が2〜10重量%である、請求項1から6のいずれかに記載の染色組成物。
- 298Kにおいて1003より大きく1040kg・m-3未満の密度を有する、請求項5に記載の染色組成物。
- レオメーターを用いて測定する際に、少なくとも2.0mPa.sの粘度を有する、請求項5〜7のいずれかに記載の染色組成物。
- 染色組成物中の生体染料の濃度が、0.001〜2重量%である、請求項1から9のいずれかに記載の染色組成物。
- 生体染料および密度増大化合物を液体中に溶解し、任意選択により前記液体に塩を溶解して、前記液体の容量オスモル濃度を250から400mosmol/Lの間の値に調節する工程を含む、請求項1から10のいずれかに規定される染色組成物を調製するための方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10159021A EP2371395A1 (en) | 2010-04-01 | 2010-04-01 | Staining Composition |
EP10159021.4 | 2010-04-01 | ||
EP10164866A EP2392355A1 (en) | 2010-06-03 | 2010-06-03 | Staining composition |
EP10164866.5 | 2010-06-03 | ||
PCT/NL2011/050218 WO2011122947A1 (en) | 2010-04-01 | 2011-04-01 | Staining composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015236602A Division JP2016041747A (ja) | 2010-04-01 | 2015-12-03 | 染色組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013523725A JP2013523725A (ja) | 2013-06-17 |
JP5889273B2 true JP5889273B2 (ja) | 2016-03-22 |
Family
ID=43901255
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013502515A Active JP5889273B2 (ja) | 2010-04-01 | 2011-04-01 | 染色組成物 |
JP2015236602A Pending JP2016041747A (ja) | 2010-04-01 | 2015-12-03 | 染色組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015236602A Pending JP2016041747A (ja) | 2010-04-01 | 2015-12-03 | 染色組成物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US9579401B2 (ja) |
EP (1) | EP2552491B8 (ja) |
JP (2) | JP5889273B2 (ja) |
CN (1) | CN102892433A (ja) |
AU (1) | AU2011233815B2 (ja) |
CA (1) | CA2795444C (ja) |
ES (1) | ES2670818T3 (ja) |
WO (1) | WO2011122947A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2673553C1 (ru) * | 2018-03-06 | 2018-11-28 | Закрытое акционерное общество "Оптимедсервис" | Витальный краситель для контрастирования внутриглазных структур заднего сегмента глаза |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11293870B2 (en) | 2013-03-29 | 2022-04-05 | Mie University | Vital stain |
WO2015066296A1 (en) | 2013-10-31 | 2015-05-07 | Beth Israel Deaconess Medical Center | Near-infrared fluorescent nerve contrast agents and methods of use thereof |
ES2929194T3 (es) * | 2013-10-31 | 2022-11-25 | Beth Israel Deaconess Medical Ct Inc | Agentes de obtención de bioimágenes de contraste fluorescentes en el infrarrojo cercano y métodos de uso de los mismos |
JPWO2015151939A1 (ja) * | 2014-03-31 | 2017-04-13 | 国立大学法人名古屋大学 | 内境界膜剥離モデル |
EP3268715A1 (en) * | 2015-03-11 | 2018-01-17 | Timothy Ragan | System and methods for serial staining and imaging |
US11007282B2 (en) | 2015-05-11 | 2021-05-18 | Dicronis Sagl | Compositions for circulatory system visualization |
US20210213144A1 (en) * | 2016-04-22 | 2021-07-15 | Vitreq B.V. | Ophthalmic dye composition |
JP2019532066A (ja) * | 2016-10-06 | 2019-11-07 | ユニヴァーシタ パボル ヨゼフ シャファーリク ブ コシツェ | 混合造影剤およびその使用 |
CN108088781B (zh) * | 2016-11-23 | 2020-07-21 | 上海迈泰君奥生物技术有限公司 | 一种用于细胞计数仪的试剂组合 |
CN107167357B (zh) * | 2017-06-22 | 2020-05-15 | 崔舜� | 基于对比染色的深部真菌形态学快速检测方法及试剂 |
CN109568177A (zh) * | 2017-09-28 | 2019-04-05 | 上海氪励铵勤科技发展有限公司 | 一种组合产品及其使用和制备方法 |
WO2019068355A1 (en) | 2017-10-06 | 2019-04-11 | Alfa Instruments S.R.L. | BLUE GLYING (BBG) COLOR DERIVATIVES AND COLORING COMPOUNDS COMPRISING THEM FOR SELECTIVELY COLORING BIOLOGICAL SUBSTRATES |
RU2669945C1 (ru) * | 2017-12-20 | 2018-10-17 | Закрытое акционерное общество "Оптимедсервис" | Способ экспресс-оценки витального красителя для контрастирования внутриглазных структур заднего сегмента глаза |
EP4031069A1 (en) | 2019-09-20 | 2022-07-27 | Niios-USA Inc. | Donor overlay for treatment or alleviation of anterior corneal disorders |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3920810A (en) | 1974-04-23 | 1975-11-18 | Burton Parsons And Company Inc | Polyacrylamide containing ophthalmic solutions |
SE454842B (sv) * | 1984-11-01 | 1988-06-06 | Pharmacia Ab | Komposition for anvendning vid oftalmologiska applikationer innehallande en vattenlosning av en hogmolekyler polymer och ett lost polymert fergemne |
US5409904A (en) | 1984-11-13 | 1995-04-25 | Alcon Laboratories, Inc. | Hyaluronic acid compositions and methods |
US4983585A (en) * | 1987-05-04 | 1991-01-08 | Mdr Group, Inc. | Viscoelastic fluid for use in surgery and other therapies and method of using same |
JP3039594B2 (ja) * | 1993-10-08 | 2000-05-08 | 株式会社日立製作所 | 染色試薬およびその使用方法 |
EP0963759A1 (en) | 1998-05-08 | 1999-12-15 | Gerrit Reinold Jacob Melles | The use of a vital dye for facilitating surgical procedures for cataract extraction |
EP0974367A1 (en) | 1998-05-08 | 2000-01-26 | Gerrit Reinold Jacob Melles | The use of a vital dye for facilitating surgical procedures for vitreo-retinal surgery |
EP1132065A1 (en) | 2000-03-07 | 2001-09-12 | Gerrit Reinold Jacob Melles | Coloured visco-elastic composition |
US6692526B1 (en) | 2000-03-15 | 2004-02-17 | Michael E. Snyder | Ophthalmological surgery colorant and delivery system |
WO2002040056A2 (en) * | 2000-11-06 | 2002-05-23 | Alcon, Inc | Carrageenan viscoelastics for ocular surgery |
US7611711B2 (en) * | 2001-01-17 | 2009-11-03 | Vegenics Limited | VEGFR-3 inhibitor materials and methods |
US6802829B2 (en) | 2001-11-16 | 2004-10-12 | Infinite Vision, Llc | Spray device |
US20050031540A1 (en) | 2001-11-20 | 2005-02-10 | Nielsen Per Julius | Visco dye |
US20060073184A1 (en) * | 2004-09-29 | 2006-04-06 | Bausch & Lomb Inc. | Viscoelastic composition, methods of use and packaging device with anti-oxidant |
WO2006062233A1 (en) | 2004-12-06 | 2006-06-15 | National University Corporation Kyushu University | A staining composition for staining an ophthalmic membrane |
EP1733744A1 (en) | 2005-06-17 | 2006-12-20 | Ludwig-Maximilians-Universität München | Method, dye and medicament for staining the internal limiting membrane and/or the capsule of an eye |
US20070253909A1 (en) | 2006-05-01 | 2007-11-01 | Medi-Flex, Inc. | Aqueous Antiseptic Solution and Compatible Cationic Dye for Staining Skin |
US20110194135A1 (en) | 2006-08-03 | 2011-08-11 | Hayden Hamilton | Print View With Easy Page Removal |
BRPI0714754A2 (pt) | 2006-09-08 | 2013-05-14 | Foamix Ltd | composiÇço tàpica colorida ou colorÍvel, mÉtodo para a mudanÇa de cor de uma composiÇço tàpica colorida ou colorÍvel e kit para aplicaÇço tàpica |
DE102006056558A1 (de) | 2006-11-30 | 2008-06-05 | Niederdellmann, Christoph, Dr. | Fluid zur intraokularen Verwendung |
BRPI0822572A2 (pt) * | 2008-03-24 | 2015-06-23 | Univ Texas | Terapia guiada por imagem de doença moicardial, composição manufaturamento e aplicações |
DE102008064065B9 (de) | 2008-12-19 | 2011-01-05 | Fluoron Gmbh | Farbstofflösung |
EP2542643A4 (en) * | 2010-03-01 | 2013-08-28 | Univ Florida | NEAR-INFRARED-INDOCYANINE-GREEN-DOTED MULTIMODAL SILICONE NANOPARTICLES AND METHOD FOR THE PRODUCTION THEREOF |
BR112012022775A2 (pt) * | 2010-03-10 | 2016-07-19 | Nogra Pharma Ltd | composições para a lavagem, do cólon e métodos para a produção e utilização das mesmas |
-
2011
- 2011-04-01 ES ES11714127.5T patent/ES2670818T3/es active Active
- 2011-04-01 AU AU2011233815A patent/AU2011233815B2/en active Active
- 2011-04-01 CN CN2011800180032A patent/CN102892433A/zh active Pending
- 2011-04-01 WO PCT/NL2011/050218 patent/WO2011122947A1/en active Application Filing
- 2011-04-01 JP JP2013502515A patent/JP5889273B2/ja active Active
- 2011-04-01 CA CA2795444A patent/CA2795444C/en active Active
- 2011-04-01 EP EP11714127.5A patent/EP2552491B8/en active Active
- 2011-04-01 US US13/638,105 patent/US9579401B2/en active Active
-
2015
- 2015-12-03 JP JP2015236602A patent/JP2016041747A/ja active Pending
-
2017
- 2017-02-02 US US15/422,961 patent/US10426849B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2673553C1 (ru) * | 2018-03-06 | 2018-11-28 | Закрытое акционерное общество "Оптимедсервис" | Витальный краситель для контрастирования внутриглазных структур заднего сегмента глаза |
Also Published As
Publication number | Publication date |
---|---|
US10426849B2 (en) | 2019-10-01 |
CA2795444C (en) | 2020-06-16 |
US20170258939A1 (en) | 2017-09-14 |
AU2011233815B2 (en) | 2015-03-19 |
EP2552491B8 (en) | 2018-04-18 |
EP2552491B1 (en) | 2018-03-07 |
AU2011233815A1 (en) | 2012-10-18 |
ES2670818T3 (es) | 2018-06-01 |
US20130045167A1 (en) | 2013-02-21 |
JP2013523725A (ja) | 2013-06-17 |
JP2016041747A (ja) | 2016-03-31 |
EP2552491A1 (en) | 2013-02-06 |
WO2011122947A1 (en) | 2011-10-06 |
CA2795444A1 (en) | 2011-10-06 |
US9579401B2 (en) | 2017-02-28 |
CN102892433A (zh) | 2013-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5889273B2 (ja) | 染色組成物 | |
JP3469199B2 (ja) | 白内障摘出の外科手術手技を容易にする生体染色色素の使用 | |
EP2620144A1 (en) | Staining Composition | |
Rodrigues et al. | The use of vital dyes in ocular surgery | |
JP4018389B2 (ja) | 着色粘弾性組成物 | |
US20080206149A1 (en) | Method, dye and medicament for staining the internal limiting membrane, epiretinal membrane, the vitreous and/or the capsule of an eye | |
JP3469198B2 (ja) | 硝子体網膜手術の外科手術手技を容易にする生体染色色素の使用 | |
EP2392355A1 (en) | Staining composition | |
AU2015202819B2 (en) | Staining composition | |
EP2371395A1 (en) | Staining Composition | |
Grisanti et al. | Safety parameters for indocyanine green in vitreoretinal surgery | |
WO2018217088A1 (en) | Staining composition with improved staining intensity | |
US20130272962A1 (en) | Staining agent for corneal staining | |
JP3953322B2 (ja) | 眼球の前部水晶体嚢を可視化するためのトリパンブルーの使用 | |
Dipta et al. | Vital Stains in Retina and Vitreous | |
JP2012236077A (ja) | 眼球の前部水晶体嚢を可視化するためのトリパンブルーの使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130909 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140929 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150129 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151203 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20151214 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160118 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5889273 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |